JAMA da yeni yayınlanan bir araştırmada ilk defa uzun süreli kalsiyum kanal blokeri kullan kadınlarda meme kanseri riskinin iki misli arttığı, buna mukabil ACEİ (anjitonsin inhibitörleri) kullananlarda kanser riskinin azaldığı gösterildi.
İlk uzun süreli gözlemsel çalışmada 10 sene ve daha uzun süre kalsiyum antagonisti kullanan kadınlarda invazif duktal kanser ve invazif lobuler meme kanserleri kullanmayanlara nazaran 2.4-2.6 misli daha fazla, ACE inhibitörü kullananlarda ise 0.3 daha az görülmüş. ABD de 2010 yılında yaklaşık 98 milyon kişi kalsiyum antagonisti kullanmış.
Use of Antihypertensive Medications and Breast Cancer Risk Among Women Aged 55 to 74 Years ONLINE FIRST
Christopher I. Li, MD, PhD1; Janet R. Daling, PhD1; Mei-Tzu C. Tang, PhD1; Kara L. Haugen, MS1; Peggy L. Porter, MD1,2; Kathleen E. Malone, PhD1
JAMA Intern Med. 2013;():-. doi:10.1001/jamainternmed.2013.9071.
Published online August 5, 2013
Abstract
Importance Antihypertensive agents are the most commonly prescribed class of medications in the United States. Evidence regarding the relationship between different types of antihypertensives and breast cancer risk is sparse and inconsistent, and prior studies have lacked the capacity to assess impacts of long-term use.
Objective To evaluate associations between use of various classes of antihypertensive medications and risks of invasive ductal and invasive lobular breast cancers among postmenopausal women.
Design, Setting, and Participants Population-based case-control study in the 3-county Seattle–Puget Sound metropolitan area. Participants were women aged 55 to 74 years, 880 of them with invasive ductal breast cancer, 1027 with invasive lobular breast cancer, and 856 with no cancer serving as controls.
Exposures Recency and duration of use of antihypertensive medications.
Main Outcomes and Measures Risks of invasive ductal and invasive lobular breast cancers.
Results Current use of calcium-channel blockers for 10 or more years was associated with higher risks of ductal breast cancer (odds ratio [OR], 2.4; 95% CI, 1.2-4.9) (P = .04 for trend) and lobular breast cancer (OR, 2.6; 95% CI, 1.3-5.3) (P = .01 for trend). This relationship did not vary appreciably by type of calcium-channel blocker used (short-acting vs long-acting, dihydropyridines vs non-dihydropyridines). In contrast, use of diuretics, β-blockers, and angiotensin II antagonists were not associated with risk.
Conclusions and Relevance While some studies have suggested a positive association between calcium-channel blocker use and breast cancer risk, this is the first study to observe that long-term current use of calcium-channel blockers in particular are associated with breast cancer risk. Additional research is needed to confirm this finding and to evaluate potential underlying biological mechanisms.